Alejandro (Alex) Barbagelata (@barba001barbage) profile picture

Physician, Invasive Cardiologist, Heart Failure, Scientist (Adj Profesor at Duke University), Clinical Trialist. Interested in cardiovascular innovations

United States
Joined July 2013
Photo by Alejandro (Alex) Barbagelata (@barba001barbage)Photo by Alejandro (Alex) Barbagelata (@barba001barbage)Photo by Alejandro (Alex) Barbagelata (@barba001barbage)Photo by Alejandro (Alex) Barbagelata (@barba001barbage)Photo by Alejandro (Alex) Barbagelata (@barba001barbage)Photo by Alejandro (Alex) Barbagelata (@barba001barbage)Photo by Alejandro (Alex) Barbagelata (@barba001barbage)Photo by Alejandro (Alex) Barbagelata (@barba001barbage)Photo by Alejandro (Alex) Barbagelata (@barba001barbage)Photo by Alejandro (Alex) Barbagelata (@barba001barbage)
AHA 2026 Series | AI may change how we diagnose coronary disease. But did PARAMOUNT improve patient outcomes? Not yet. PARAMOUNT (AHA 2026) randomized 523 symptomatic patients to AI-enabled plaque analysis vs usual functional testing. The AI-guided strategy achieved a win ratio of 2.00 (p<0.0001). But look beneath the headline: • Diagnostic certainty improved: 40% vs 19%. • LDL-C reduction was modestly greater: −22.7 vs −15.1 mg/dL. • Invasive angiography rates were virtually identical: 8.0% vs 7.7%. • Revascularization was not significantly different. • No clinical outcome benefit was demonstrated. The important distinction: The win ratio was driven almost entirely by physician-reported diagnostic certainty and LDL-C reduction, not fewer procedures or better clinical outcomes. AI-enabled plaque analysis may help physicians identify atherosclerosis earlier and intensify preventive treatment. But better diagnosis is not automatically better prognosis. We still need longer follow-up and trials showing fewer MIs, cardiovascular deaths, or other meaningful clinical events. Promising technology. Encouraging management data. Clinical benefit remains unproven.
16
9
165
39,164
At the AHA presidential reception with Manesh, Chris Kramer and Hani Najm (past and next ACC president)
4
27
1,853
Global community at the American Heart Chicago
1
1
4
566
Alejandro (Alex) Barbagelata retweeted
Is high LDL cholesterol (or apoB) harmful ONLY with poor metabolic health, characterized by low HDLc? New study from preeminent lipidologist Sniderman: "when HDL-C is high ... effect of changing apoB vanishes" PS: A low-carb diet potently increases HDLc academic.oup.com/eurjpc/adva…
36
101
29
392
68,887
Alejandro (Alex) Barbagelata retweeted
Just published @ScienceMagazine Higher medical accuracy at lower cost A 3-agent AI for sequential diagnosis nearly doubled accuracy compared with physicians for >300 @NEJM CPC cases and >300 ER cases AND substantially lowered cost, also exceeded performance of many AI models, physicians plus AI @HarshaNori @erichorvitz @Dominic1King @mustafasuleyman
40
129
19
497
62,244
Alejandro (Alex) Barbagelata retweeted
In the phase 3 TRIUMPH-1 trial involving patients with obesity, retatrutide, a triple hormone receptor agonist, resulted in substantial weight reduction and a decrease in knee osteoarthritis pain and obstructive sleep apnea events. Full trial results: nej.md/4ycgSHz
26
262
112
1,089
417,845
Alejandro (Alex) Barbagelata retweeted
Presented at #ESCCongress: In patients with severe tricuspid regurgitation and heart failure, transcatheter tricuspid-valve repair plus medical therapy was superior to medical therapy alone in reducing hospitalizations for heart failure and deaths. Full TRIC-I-HF trial results: nej.md/4ilZJGr @escardio
3
116
12
259
46,613
Alejandro (Alex) Barbagelata retweeted
🫀#ESCCongress wraps in Munich with practice-shaping trials. Cardiology keeps moving fast. #Cardiology #CardioTwitter #CardioEd @escardio @ESC_President @CMichaelGibson @JGrapsa @drjohnm @DrMarthaGulati @ErinMichos @mirvatalasnag @Drroxmehran @DFCapodanno @DLBHATTMD
1
79
4
230
18,739
Alejandro (Alex) Barbagelata retweeted
NEW 2026 #ESCGuidelines for the management of heart failure 👇ow.ly/km3250ZGoe9 #ESCCongress
5
877
78
1,865
205,137
Alejandro (Alex) Barbagelata retweeted
NEW 2026 #ESCGuidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA) 👇 ow.ly/jI4f50ZGocP #ESCCongress
3
384
19
784
88,116
Alejandro (Alex) Barbagelata retweeted
Presented at #ESCCongress: In pulmonary hypertension associated with left heart disease and heart failure, pulmonary-artery denervation reduced clinical worsening and recurrent heart failure events as compared with guideline-directed medical therapy alone. Full PADN-HF-PH trial results: nej.md/4wCHY9u @escardio
3
76
11
207
38,495
Alejandro (Alex) Barbagelata retweeted
Was honored to be discussant for landmark TRIC-I-HF Trial here @escardio See @NEJM simultaneous publication bit.ly/4cRywb3 #ESCCongress @j_hausleiter @PhilippLurz
1
47
153
8,316
A major step forward for women at #ESCCongress 🫀 The new 5th Universal Definition of MI explicitly requires sex-specific 99th-percentile troponin thresholds recognizing that using the same cutoff in women and men can systematically underdiagnose myocardial injury in women It also recognizes SCAD, coronary vasospasm & embolism as causes of primary MI—mechanisms especially important in women. Women’s heart attacks don’t always look like men’s. Our definitions finally reflect that. We wanted to enforce this in the Cheat Pain guidelines but we didn’t have enough data in the US at that time. Glad this has changed! #CardioTwitter #WomensHeartHealth #MyocardialInfarction
🤖 Made with AI
9
95
4
264
27,265
Alejandro (Alex) Barbagelata retweeted
New Strategies for Prevention and Coronary Syndromes - HOTLINE 2 & 3 👇 #ESCCongress
2
55
1
172
13,676
Met-HEFT at #ESCCongress Does metformin provide CV benefit beyond glucose lowering in HFrEF? 940 patients (❌mostly men!) with HFrEF + diabetes/prediabetes randomized to metformin 🆚 placebo ❌ No reduction in death, worsening HF, MI or stroke: 25.1% vs 23.4% HR 1.10 (95% CI 0.84–1.42), P=.48 Metformin remains useful for glycemic control—but no evidence of independent cardioprotection in HFrEF. Another reason to control glucose with other drugs that can improve CV outcomes/risk #HeartFailure #CardioTwitter
2
9
46
2,511
Alejandro (Alex) Barbagelata retweeted
This is what 40,000 cardiologists look like when using public transport to go to their event #ESCCongress at 8 am in Munchen….
8
23
3
260
25,419
Alejandro (Alex) Barbagelata retweeted
What a team. 🩵🇦🇷
93
1,812
83
17,597
374,958